Donald Trump has signed an executive order directing the federal government to accelerate research into psychedelic drugs, including the compound ibogaine, as potential treatments for mental health conditions, according to multiple national news outlets that reviewed the order.
CBS News, PBS, ABC News and Al Jazeera each reported on Friday that the order is aimed at speeding up how federal agencies study and review psychedelic-assisted therapies. Their accounts describe a directive focused on exploring whether drugs long associated with counterculture and strict criminal penalties could play a larger role in treating conditions such as depression and post-traumatic stress disorder.
While the full text of the order had not been widely published at the time of those reports, all four outlets independently characterized it as an instruction to federal agencies to prioritize and streamline research on psychedelic medicines.
What the executive order does
The order instructs federal agencies to hasten research and regulatory review of psychedelic substances for mental health treatment, according to reporting by CBS News, PBS and ABC News. Those outlets describe the move as an attempt to reduce bureaucratic delays that have historically slowed clinical studies of drugs that are tightly controlled under federal law.
PBS reported that the order covers a range of psychedelic compounds. CBS News and ABC News each noted that ibogaine, a psychoactive substance derived from an African shrub, is specifically mentioned as one of the drugs to be studied for possible therapeutic use.
Al Jazeera, citing its review of the action, similarly described the order as designed to “speed up” the federal process for evaluating psychedelic therapies. Across the four reports, the language around “hastening,” “accelerating” or “speeding” research appears repeatedly in reference to the order’s core purpose.
The outlets report that the order centers on mental health treatment rather than on broader drug policy. Within that frame, the directive is described as seeking to clarify and coordinate how agencies handle applications to study psychedelic drugs in clinical settings.
Why psychedelics and ibogaine are in focus
Psychedelics are a class of drugs that alter perception and cognition, often producing intense changes in mood and sense of self. Ibogaine, one of the substances singled out in the reporting on the order, is a naturally occurring psychedelic compound found in the root bark of the iboga plant.
CBS News reported that ibogaine is of particular interest because of its potential role in treating addiction and other mental health conditions, though it remains a controlled substance and is not approved as a medicine in the United States. ABC News and PBS each placed ibogaine within a wider group of psychedelics that researchers have been studying in recent years under tightly regulated conditions.
The outlets’ coverage links the order to a growing body of clinical research into psychedelic-assisted therapy, although they do not claim that the order itself changes the legal status of any drug. Instead, they describe it as an attempt to make it easier for scientists and medical institutions to obtain approvals to study these substances and to move promising treatments through the federal review process.
Al Jazeera’s report noted that Trump signed the order at a public event and emphasized the focus on mental health treatment. Its coverage, along with that of ABC News and PBS, framed the action as part of a broader debate over how quickly the federal government should respond to emerging evidence on psychedelic therapies.
How the federal process could change
Across the four outlets, the reporting suggests that the order is aimed at the pace and coordination of federal review, rather than at rewriting drug laws directly.
PBS described the order as directing federal agencies to review how they handle psychedelic research applications and to move more quickly on evaluating potential therapies. ABC News similarly reported that the order is intended to “accelerate” research and regulatory consideration of psychedelic drug therapies, indicating a push for shorter timelines and clearer pathways for clinical trials.
CBS News’ account underscored that the order is framed around mental health treatment, particularly conditions that have been difficult to treat with existing medications. According to that reporting, the directive is expected to involve agencies that oversee drug scheduling, medical research and approval of new therapies, though specific agencies were not named in the summaries available.
None of the four outlets reported that the order immediately authorizes the medical use of any psychedelic drug. Instead, they consistently described it as a research-focused measure that could, over time, influence whether psychedelic therapies are considered for approval if clinical trials demonstrate safety and effectiveness.
Reactions and what is at stake
The outlets’ initial coverage focused primarily on the substance of the order and the policy shift it represents, rather than on a wide range of reactions. However, their reporting points to several stakes in the decision.
ABC News and PBS both situated the order within ongoing efforts to find new treatments for mental health conditions, including depression and PTSD, that affect millions of Americans. By highlighting the mental health focus, the coverage suggests that the order could influence how quickly new therapeutic options are evaluated for people who have not responded to existing treatments.
CBS News’ emphasis on ibogaine and other psychedelics as research targets underscores another stake: whether the federal government will treat these substances primarily as law-enforcement concerns or as potential medical tools subject to scientific evaluation. The order, as described, leans toward the latter by prioritizing research pathways.
Al Jazeera’s report, which noted that Trump was joined by public figures at the signing, framed the event as a visible signal of support for psychedelic research. That visibility may encourage more institutions to consider pursuing studies, though the outlets did not report specific institutional commitments in response to the order.
Because the reporting is based on early coverage, it does not yet capture detailed responses from medical associations, regulators or patient groups. Those reactions are likely to shape how the order is implemented and how much practical change it brings to the research landscape.
What to watch next
In the coming days and weeks, attention is likely to turn to how federal agencies interpret and implement the directive described in the order. PBS and ABC News both indicated that the order is meant to hasten review processes, which suggests that agencies responsible for drug research and approval may issue guidance or internal timelines reflecting the new priorities.
Reporters at CBS News, PBS, ABC News and Al Jazeera have all treated the order as a significant signal on psychedelic research. Follow-up coverage from these and other outlets will be key to tracking whether agencies announce new research programs, adjust how they handle applications to study psychedelics such as ibogaine, or set out clearer criteria for evaluating psychedelic-assisted therapies.
As more details of the order’s text and implementation emerge, they will help clarify how much it changes day-to-day practice for researchers and clinicians. For now, the consistent reporting across four major outlets points to a notable federal push to examine psychedelic drugs as potential tools in mental health treatment, with the practical impact dependent on the steps agencies take next.
